ClinicalTrials.gg
RecruitingNCT07863024Updated Nov 18, 2026

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

A Phase 1/2 interventional study of REGN13089-M404-M2980 in Advanced Solid Tumors, sponsored by Regeneron Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Updated Nov 18, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,143 studies in Carcinoma, Renal Cell with a site in United States — 155 open to participants now, 279 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
94th of 1,009
320 · median 40
Started
2026
with 43 others
Phase 1/2
147 of 1,143
31 open now
Primary completion
2031-03
later than 259 of 277 live
Registered
1,140th of 1,143
by date

Among the 1,143 studies in Carcinoma, Renal Cell with a site in United States, this one is the 94th largest by planned enrollment of the 1,009 interventional ones that give a count, is one of 44 that started in 2026, is one of 147 in phase 1/2, reaches primary completion later than 259 of the 277 other live ones, and was the 1,140th registered.

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

155 of the 1,143 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

149 more — sign in →

All 155 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,143 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).

The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.

The study is looking at:

  • What side effects the study drug might cause
  • How well the study drug works
  • How much of the study drug is in the blood at different times
  • If the body reacts to the study drug, in a way that may cause the study drug to not work as well
  • What is the best dose of the study drug for treating previously treated, advanced solid tumors
03

Conditions studied

  • Advanced Solid Tumors

Keywords

  • ADC
  • Antibody-drug conjugate
  • Advanced cancer
  • Advanced solid malignancy
  • Clear cell renal cell carcinoma
  • Colorectal cancer
  • First-in-human
  • FIH
  • Gastric cancer
  • Gastroesophageal junction cancer
  • MET
  • METxMET antibody-drug conjugate
  • Metastatic
  • Metastatic solid tumor
  • Non-small cell lung cancer
  • NSCLC
  • Papillary renal cell carcinoma
  • Solid neoplasm
  • Unresectable
  • Unresectable solid tumor
  • Uveal melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
  2. Participants must not be candidates for curative surgery or radiation
  3. Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment disease, or intolerance of the therapy as described in the protocol
  4. Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
  5. At least 1 lesion that is measurable by 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
  6. (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an agent or investigational device as described in the protocol
  2. Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a of 14 days from first administration of study intervention.
  3. Has undergone major surgery within the 14 days prior to first administration of study intervention
  4. Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
  5. Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
  6. Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
  7. Known active or untreated or spinal cord compression. Participants are eligible if central nervous system (CNS) are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.

Note: Other protocol defined inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Drug: REGN13089-M404-M2980

  • Experimental
    Part 2: Dose Expansion

    Drug: REGN13089-M404-M2980

Interventions

  • DrugREGN13089-M404-M2980

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicities (DLTs)

    Part 1 (Dose Escalation)

    Time frame: Up to 21 days

  2. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Part 1 (Dose Escalation)

    Time frame: Up to approximately 5 years

  3. Occurrence of Serious Adverse Events (SAEs)

    Part 1 (Dose Escalation)

    Time frame: Up to approximately 5 years

  4. Occurrence of adverse event of special interests (AESIs)

    Part 1 (Dose Escalation)

    Time frame: Up to approximately 5 years

  5. Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Objective response (investigator assessed) per RECIST 1.1

    Part 1 (Dose Escalation)

    Time frame: Up to approximately 5 years

  2. Concentrations of ADC

    Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  3. Concentrations of total antibody

    Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  4. Concentrations of payload (ProDXd and DXd)

    Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  5. Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980

    Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  6. Magnitude of ADA against REGN13089-M404-M2980

    Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  7. Duration of response per RECIST 1.1

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  8. Time to response per RECIST 1.1

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  9. Progression-free survival per RECIST 1.1

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  10. Overall survival

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  11. Occurrence of TEAEs considered clinically significant

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

  12. Laboratory abnormalities considered clinically significant

    Part 2 (Dose Expansion)

    Time frame: Up to approximately 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2031, 52 months after the start.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 52 months is below that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartActual
Oct 28, 2026was Nov 2026
Primary completionEst.
Mar 10, 2031
CompletionEst.
Mar 10, 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in United States
Show site
  • Carolina BioOncology Institute · Huntersville, United States
Nov 18, 2026
Start date
Nov 23, 2026→Oct 28, 2026 (actual)
Nov 18, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Carolina BioOncology Institute · Huntersville, United States
    Start date Nov 23, 2026→Oct 28, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863024
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 28, 2026
Primary completion
Mar 10, 2031 (estimated)
Completion
Mar 10, 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion